Literature DB >> 19203094

Type 1 diabetes: chronic progressive autoimmune disease.

Li Zhang1, Roberto Gianani, Maki Nakayama, Edwin Liu, Masakazu Kobayashi, Erin Baschal, Liping Yu, Sunanda Babu, Abby Dawson, Kelly Johnson, Mohamed Jahromi, Theresa Aly, Pamela Fain, Jennifer Barker, Marian Rewers, George S Eisenbarth.   

Abstract

A wealth of data in animal models indicates that type 1A diabetes results from T cell-mediated specific destruction of islet beta cells. There is evidence for the NOD mouse model that insulin is the primary autoantigen and a specific insulin peptide B:9-23 is central to pathogenesis. It is also now possible to predict the development of type 1A (immune mediated) diabetes for the great majority of individuals with a combination of genetic, immunological and metabolic parameters. Such prediction is possible because of the chronic nature of the autoimmunity and loss of beta cell function that precedes the disease. Given the ability to predict type 1A diabetes trials at all stages of the disorder to prevent beta cell destruction are now possible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19203094     DOI: 10.1002/9780470697405.ch7

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  16 in total

1.  Autoantibodies and high-risk HLA susceptibility markers in first-degree relatives of Brazilian patients with type 1 diabetes mellitus: a progression to disease based study.

Authors:  L I Alves; E Davini; M R Correia; R T Fukui; R F Santos; M R Cunha; D M Rocha; W M G Volpini; M E R Silva
Journal:  J Clin Immunol       Date:  2012-03-09       Impact factor: 8.317

Review 2.  Beta cell regeneration in human pancreas.

Authors:  Roberto Gianani
Journal:  Semin Immunopathol       Date:  2010-12-25       Impact factor: 9.623

3.  miR-101a and miR-30b contribute to inflammatory cytokine-mediated β-cell dysfunction.

Authors:  Ying Zheng; Zhen Wang; Yiting Tu; Hongwei Shen; Zhijie Dai; Jian Lin; Zhiguang Zhou
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

4.  Novel autoantigens in type 1 diabetes.

Authors:  Shuhong Han; William Donelan; Hai Wang; Westley Reeves; Li-Jun Yang
Journal:  Am J Transl Res       Date:  2013-05-24       Impact factor: 4.060

5.  Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development.

Authors:  Zuoxiang Xiao; Abdiaziz S Mohamood; Sophia Uddin; Rachel Gutfreund; Chiaki Nakata; Andrew Marshall; Hiroaki Kimura; Patrizio Caturegli; Karl L Womer; Yanfei Huang; Chunfa Jie; Shukti Chakravarti; Jonathan P Schneck; Hideo Yagita; Abdel Rahim A Hamad
Journal:  Am J Pathol       Date:  2011-06-15       Impact factor: 4.307

6.  The PTPN22 1858T allele but not variants in the proximal promoter region of IL-21 gene is associated with the susceptibility to type 1 diabetes and the presence of autoantibodies in a Brazilian cohort.

Authors:  D T O Mainardi-Novo; A S Santos; R T Fukui; M Gamberini; M R S Correia; M O Ruiz; C L P Mangueira; S R Matioli; D M Vasconcelos; M E R Silva
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

7.  Occurrence of type 1 diabetes in graves' disease patients who are positive for antiglutamic Acid decarboxylase antibodies: an 8-year followup study.

Authors:  Matsuo Taniyama; Akira Kasuga; Chieko Nagayama; Koichi Ito
Journal:  J Thyroid Res       Date:  2010-12-28

8.  Diubiquitin (Ubd) is a susceptibility gene for virus-triggered autoimmune diabetes in rats.

Authors:  L Cort; M Habib; R A Eberwine; M J Hessner; J P Mordes; E P Blankenhorn
Journal:  Genes Immun       Date:  2014-01-23       Impact factor: 2.676

9.  Involvement of circRNAs in Proinflammatory Cytokines-Mediated β-Cell Dysfunction.

Authors:  Zhen Wang; Chao Deng; Ying Zheng
Journal:  Mediators Inflamm       Date:  2021-05-04       Impact factor: 4.711

10.  Insulinization: A promising strategy for the treatment of type 2 diabetes mellitus.

Authors:  Guo Lian; Xu Yue; Zhang Xianxiang; Luo Yong; Liu Weijuan; Chen Bing
Journal:  Exp Ther Med       Date:  2013-09-13       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.